doi: 10.1089/pancan.2020.0003. eCollection 2020.
- PMID: 32642629
- PMCID: PMC7337241
- DOI: 10.1089/pancan.2020.0003
Abstract
Purpose: New tetrahydrocannabinolic acid (THCA) derivatives ALAM027 and ALAM108 were proposed for the treatment of the pancreatic cancer disease.
Methods: The in vitro effect of new cannabinoids ALAM027 and ALAM108 was tested against PANC-1 and AsPC-1 cell lines by CellTiter Glo assay. Pancreatic cancer xenograft model was used for the in vivo anticancer activity study of these compounds on PANC-1 cells.
Results: The in vitro study of new cannabinoids showed greater activity of ALAM108 than ALAM027 both for PANC-1 and AsPC-1 cells. The in vivo study of new cannabinoids on PANC-1 cells showed that their oral administration was effective in reducing tumor volume and tumor weight, and did not lead to any discomfort and weight loss of mice.
Conclusion: The cannabinoids ALAM108 and ALAM027 inhibited the tumor growing 1.6-2 times in mice with human PANC-1 cells.
Keywords: AsPC-1, PANC-1, THCA, cannabinoids, in vitro, in vivo
© Alexander Aizikovich 2020; Published by Mary Ann Liebert, Inc.
Conflict of interest statement
No competing financial interests exist.
Figures
References
-
- Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921 – PubMed
- Cridge BJ, Rosengren RJ. Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Manage Res. 2013;5:301–313 – PMC – PubMed
- Dariš B, Tancer Verboten M, Željko Knez, et al. Cannabinoids in cancer treatment: therapeutic potential and legislation. Bosn J Basic Med Sci. 2019;19:14–23 – PMC – PubMed
- Sharafi G, He H, Nikfarjam M. Potential use of cannabinoids for the treatment of pancreatic cancer. J Pancreatic Cancer. 2019;5:1–7 – PMC – PubMed
- Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumor agents. Nat Rev Cancer. 2012;12:436–444 – PubMed
